comparisson of gabapentne and pregabalin in controling of opioid withdrawal

A comparative study of Pregabalin and gabapentin on the control of opioid withdrawal symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201707252266N7

Enrollment

Registered

2017-08-10

Start date

2017-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opium Dependency. Mental and behavioural disorders due to use of opioids

Interventions

Intervention 1: pregabalin group:patients in this groups will be receive Bupronorphine. Bupronorphine dose will be adjusted based on patients need and all of them will be stabilized on Bupronorphine d

Treatment - Drugs

pregabalin group:patients in this groups will be receive Bupronorphine. Bupronorphine dose will be adjusted based on patients need and all of them will be stabilized on Bupronorphine during 3-5 days.

Gabapentine group: patients in this groups will be receive Bupronorphine. Bupronorphine dose will be adjusted based on patients need and all of them will be stabilized on Bupronorphine during 3-5 days

Placebo group: patients in this groups al so will be receive Bupronorphine. Bupronorphine dose will be adjusted based on patients need and all of them will be stabilized on Bupronorphine during 3-5 da

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having DSM-V criteria for drug dependence; regular orally/smoking daily consumption of opium; using no other medication including psychiatric drugs and also other substances except cigarette; not taking pain medications; absence of other comorbid psychiatric disorders; not having any special disease which causes opium withdrawal prohibition; no contraindication for pregabalin and gabapentin consumption . Exclusion criteria : lack of patients' interest for participation and continuation of study; any ethical or medical conflict for continuation; incidence of any physical/mental complication that needs special interventions. ;pregnancy and brestfeeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of opium withdrawal. Timepoint: first, 7th, 15th and 22th days. Method of measurement: Qustionair.	—

Secondary

Measure	Time frame
Drugs sideffects. Timepoint: first, 7th, 15th, 22th days. Method of measurement: check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholam Reza Kheirabadi

Isfahan University of Medical Sciences

kheirabadi@bsrc.mui.ac.ir+98 31 3222 2135

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026